Search

Objective To investigate the relationship between beta enolase gene two point rs121918403 (G/A), rs121918404 (G/A) polymorphism with skeletal muscle Atrophy in the patient with chronic obstructive pulmonary disease (COPD). Method Beta enolase genes were assayed by polymerase chain and one-way directed sequencing methods between 120 COPD patients and 60 age-matched controls in Kunming. Result There was no mutation in rs121918403 (G/A) and rs121918404 (G/A) of beta enolase gene in COPD patients and healthy subjects. Conclusion SNPs of two mutational sites of beta enolase are not correlated to skeletal muscle atrophy in COPD patients in Kunming. [ABSTRACT FROM AUTHOR]

Objective To investigate the effect of thoracoscopy under local anesthesia in diagnosis and treatment of tuberculous encysted pleural effusion. Method 143 patients with tuberculous encysted pleural effusion were divided into two groups according to historical comparison method: thoracoscopic group (n = 64) and control group (n =79) . The corresponding diagnosis and treatment were retrospectively analyzed, and the pathological diagnosis rate, changes in lung function, chest tightness and shortness of breath disappear, complications after treatment were compared between the two groups. Results The pathological diagnosis rate, vital capacity of lung function expected percentages ( FVC% ) and forced expiratory volume in 1 second take up of the expected (FEV1%) values in the thoracoscopic group were higher than the control group, but chest tightness, shortness of breath disappear time were lower than the control group, the differences were significant (P < 0.05) . 1 case of severe complications occurred in the thoracoscopic group. Conclusion The effect of thoracoscopy under local anesthesia is good in diagnosis and treatment of tuberculous encysted pleural effusion, it is simple and has low incidence of severe complications, so is worth clinical promotion. [ABSTRACT FROM AUTHOR]

Abstract: Carbon dioxide was photo-catalytically reduced to produce formic acid in an aqueous solution using visible light irradiation. Titania and zinc-phthalocyanine (ZnPc)-loaded titania were synthesized by a sol–gel method and in situ chemical synthesis technique. The photo-catalytic reactions were conducted in a Pyrex reactor with a visible light irradiating. XRD and DRS revealed that ZnPc was on the TiO2 surface. The optimum technique was in situ chemical synthesis and the optimum amount of ZnPc loading was 1.0wt.% for the highest dispersion among catalysts. The formic acid yield of 1.0wt.% in situ ZnPc/TiO2 was 978.6μmol/g catalyst following 10h of visible light illumination and the conversion was 0.37%. The yield was higher than those of sol–gel TiO2 and ZnPc/BH-1, whose yields were 321.0 and 756.2μmol/g catalyst, respectively. Experimental results indicated that the formic acid yield was significantly increased by loading ZnPc. ZnPc has a higher selectivity than metal catalysts for the reduction of CO2. The photo-catalytic efficiency of ZnPc/TiO2 was markedly increased because of the lowering re-combination probability for hole–electron pairs. [Copyright &y& Elsevier]

Metal ions (Cr, Ni, Co) doped titania (M-TiO2) coupled with the long after glow phosphor MgAl2O4:(Pr3+, Dy3+) particles were synthesized by the sol-gel method, with the best mass ratio of MgAl2O4:(Pr3+, Dy3+) to M-TiO2 as 4:6. MgAl2O4:(Pr3+, Dy3+)/M-TiO2 had the persistent methyl orange (MO) photocatalytic degradation ability and the photocatalytic degradation went on reacting more than 90 min in dark after turning off the light. MgAl2O4:(Pr3+, Dy3+) emitted the light as a light source in dark which was absorbed by M-TiO2. The differences of MgAl2O4:(Pr3+, Dy3+)/Cr-TiO2, MgAl2O4:(Pr3+, Dy3+)/Ni-TiO2 and MgAl2O4:(Pr3+, Dy3+)/Co-TiO2 might be attributed to the difference in the metal ions doping. The composite MgAl2O4:(Pr3+, Dy3+)/Cr-TiO2 revealed the highest ability of persistent photocatalytic degradation methyl orange. Different metal ions doping made the TiO2 with different band gap.

Background: The role of the antioxidant N-acetylcysteine (NAC) in the treatment of chronic obstructive pulmonary disease (COPD) has not been clarified as yet. In early studies, we found that the proportion of smokers with COPD having extremely slow/slow microsomal epoxide hydrolase (EPHX1) enzyme activity is significantly higher than that in healthy smokers. The purpose of this study was to evaluate whether different EPHX1 enzyme activity is related to differential therapeutic effects of treatment with NAC in COPD., Methods: A total of 219 patients with COPD were randomly allocated to an extremely slow/slow EPHX1 enzyme activity group (n=157) or a fast/normal EPHX1 enzyme activity group (n=62) according to their EPHX1 enzyme activity. Both groups were treated with NAC 600 mg twice daily for one year. The main study parameters, including forced expiratory volume in one second (FEV1), St George's Respiratory Questionnaire (SGRQ), and yearly exacerbation rate, were measured at baseline and at 6-month intervals for one year., Results: Both FEV1 and SGRQ symptom scores were improved after treatment with NAC in the slow activity group when compared with the fast activity group. Further, changes in FEV1 and SGRQ symptom score in patients with mild-to-moderate COPD were more significant than those in patients with severe-to-very severe COPD. The yearly exacerbation rates were reduced in both groups, but the reduction in the slow activity group was significantly lower than in the fast activity group., Conclusion: NAC treatment in COPD patients with extremely slow/slow EPHX1 enzyme activity improves FEV1 and the SGRQ symptom score, especially in those with mild-to-moderate COPD, and polymorphism in the EPHX1 gene may have a significant role in differential responses to treatment with NAC in patients with COPD.

Objective: To explore the relationship between the mRNA expression level of mitochondrial cytochrome oxidase and the maternal inheritance of asthma., Methods: From January to December 2009, 220 asthma patients, 162 patient kins and 260 healthy subjects were recruited from Departments of Respiratory Critical Care Medicine and Pediatric Medicine at First Affiliated Hospital, Kunming Medical College. Lung function tests were performed and serum IgE level measured. The polymorphism of mitochondrial cytochrome oxidase gene polymorphisms was detected by direct sequencing. And the peripheral level of COX mRNA was measured by reverse transcription-polymerase chain reaction (RT-PCR)., Results: No significant difference existed in age, gender among 3 groups. For 3 groups, the first second forced expiratory volume (FEV1)/forced vital capacity (FVC) were 90.6 ± 6.2, 92.3 ± 2.3, 102.3 ± 2.3 and FEV1 percentage of expected value (FEV1%) were (82.9 ± 10.8)%, (94.8 ± 5.4)% and (98.3 ± 8.6)% respectively. The lung function was not significant difference among three groups. The mRNA expression level of mitochondrial cytochrome oxidase in peripheral blood were 0.357 ± 0.217, 0.637 ± 0.473 and 0.975 ± 0.260 in the asthma, kin and control groups respectively. No significant difference existed in the expression level of COX3 mRNA among 3 groups (F = 21.45, P = 0.012). The serum level of lgE was the highest for the asthma patients. And it was significantly higher in the asthma group than that in the control group ((283.6 ± 62.4) vs (52.3 ± 13.7) µg/L, F = 48.31, P < 0.05). Moreover, the serum level of IgE was significantly higher in the kin group than that in the control group ((116.4 ± 57.5) vs (52.3 ± 13.7) µg/L, F = 20.45, P < 0.05). However, there was a negative correlation between the mRNA expression level of mitochondrial cytochrome oxidase and the serum level of IgE among 3 groups., Conclusions: The down-regulated mRNA expressin of mitochondrial cytochrome oxidase may participate in allergic inflammation by regulating the level of IgE. And the maternal inheritance of asthma is in effect.

Objective: To observe the efficacy of combination therapy with inhaled salmeterol/fluticasone and tiotropium in reducing the frequency of acute episodes of symptom exacerbation and improving lung function and health status in chronic obstructive pulmonary disease (COPD)., Methods: One hundred and twenty-six patients (M/F: 92/34) with COPD were treated in a randomised, parallel-group, controlled study with salmeterol/fluticasone (50/250 microg) twice daily and tiotropium 18 microg once daily (n = 33, M/F: 23/10); salmeterol/fluticasone (50/250 microg) twice daily (n = 32, M/F: 24/8); or tiotropium 18 microg once daily (n = 32, M/F: 23/9) for 12 months. Patients in the blank control group (n = 29, M/F: 22/7) did not receive any inhaled anticholinergic drugs, long-acting beta(2) agonists or glucocorticoid therapy. Intention-to-treat analysis (n = 161) and per-protocol analysis (n = 126, age 45 - 71 years) were performed., Results: Three active treatments significantly improved symptoms and health status. The use of rescue medication in the combination group [1 (0 - 7) time, 95% CI] was significantly decreased compared with those in the blank group [2 (0 - 29) times], salmeterol/fluticasone alone [2 (0 - 13) times], tiotropium alone [1 (0 - 11) time], F = 4.914, P < 0.01. The frequency of exacerbations in the combination group was (0.7 +/- 0.5) time, significantly lower than that in the blank group [(1.5 +/- 0.9) times], salmeterol/fluticasone alone [(1.2 +/- 0.6) times], and tiotropium alone [(1.1 +/- 0.5) times], F = 8.513, P < 0.01. The FEV(1) in the combination group after the trial was (1.19 +/- 0.03) L, significantly improved compared to that before treatment (1.09 +/- 0.04) L, a 9.5% increase, which was greater than the blank (0.9%), tiotropium alone (8.2%) and salmeterol/fluticasone alone (6.3%), t = -5.024 to -15.58, P < 0.01., Conclusion: Combination therapy with salmeterol/fluticasone and tiotropium leads to better control of symptoms and improved lung function, with no greater risk of side-effects, as compared to salmeterol/fluticasone or tiotropium alone in the treatment of COPD.

Objective: To study the diagnostic and prognostic value of procalcitonin (PCT), common inflammatory markers combining with scores for estimating organ failure of infection related organs (SOFA) in patients with sepsis in early stage., Methods: Patients were observed continuously in a perspective study with diagnostic tests. According to the definition of ACCP/SCCM Consensus Conference, patients were classified into 5 groups, including non-systemic inflammatory response syndrome (SIRS) (control) group, SIRS group, sepsis group, severe sepsis group and septic shock group. Indexes of inflammation, SOFA and concentration of PCT were determined at 24 hours, and their correlation was analyzed., Results: Two hundred and eight patients were enrolled, including 59 in non-SIRS group, 57 in SIRS group, 52 in sepsis group, 28 in severe sepsis group and 12 in septic shock group. PCT concentrations were positively correlated with the severity of sepsis. Spearman's correlation coefficient was 0.909 (P=0.000). According to the receiver operating characteristic curves (ROC-curves) analysis principle, ROC curves were drawn and areas under these curves (AUC) was calculated. In the diagnosis of sepsis, AUC values were 0.936+/-0.020 for PCT, 0.973+/-0.011 for SOFA (both P=0.000). The best cutoff values in the diagnosis of sepsis were 0.375 microg/L for PCT, and 3. 5 for SOFA score. The Youden index of PCT and SOFA scores was 0.808 and 0.801, respectively. Binary Logistic regression analysis confirmed that PCT and SOFA score were highly correlated with sepsis (OR=84.794,10.761, respectively, both P=0.000) after eliminating confusion factors including age and C-reactive protein (CRP) etc.. PCT and SOFA score could be used to predict the incidence of sepsis. SOFA score was the best prognostic indicator of sepsis (OR=2.084, P=0.0002)., Conclusion: The traditional inflammatory markers and CRP are useful parameters to differentiate SIRS from non-SIRS, but are not reliable indicators for the early diagnosis in patients with sepsis. PCT is more specific indicator in early diagnosis of sepsis to differentiate from SIRS. PCT combining with SOFA score can be used to predict the incidence of sepsis. SOFA score can be used to define objectively the severity of sepsis according to PCT level and is helpful for estimation of prognosis in patients with sepsis.